|
1
|
Naganawa Y, Ishiguro H, Kuwabara Y, et al:
Decreased expression of FBXW7 is correlated with poor prognosis in
patients with esophageal squamous cell carcinoma. Exp Ther Med.
1:841–846. 2010.PubMed/NCBI
|
|
2
|
Ando T, Ishiguro H, Kuwabara Y, et al:
Expression of ACP6 is an independent prognostic factor for poor
survival in patients with esophageal squamous cell carcinoma. Oncol
Rep. 15:1551–1555. 2006.PubMed/NCBI
|
|
3
|
Japanese Society for Esophageal Disease.
Guidelines for the Clinical and Pathologic Studies on Carcinoma of
the Esophagus. 9th edition. Kanehara Publ. Co.; Tokyo: 1999
|
|
4
|
Ando T, Ishiguro H, Kuwabara Y, et al:
Relationship between expression of 5-fluorouracil metabolic enzymes
and 5-fluorouracil sensitivity in esophageal carcinoma cell lines.
Dis Eso. 21:15–20. 2007.
|
|
5
|
Salonga D, Danenberg KD, Johnson M, et al:
Colorectal tumors responding to 5-fluorouracil have low gene
expression levels of dihydropyrimidine dehydrogenase, thymidylate
synthase, and thymidine phosphorylase. Clin Cancer Res.
6:1322–1327. 2000.
|
|
6
|
Nishimura G, Terada I, Kobayashi T, et al:
Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels
in primary colorectal cancer show a relationship to clinical
effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol
Rep. 9:479–482. 2002.PubMed/NCBI
|
|
7
|
Oguri T, Achiwa H, Bessho Y, et al: The
role of thymidylate synthase and dihydropyrimidine dehydrogenase in
resistance to 5-fluorouracil in human lung cancer cells. Lung
Cancer. 49:345–351. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Terashima M, Irunoda T, Fujiwara H, et al:
Roles of thymidylate synthase and dihydropyrimidine dehydrogenase
in tumor progression and sensitivity to 5-fluorouracil in human
gastric cancer. Anticancer Res. 22:761–768. 2002.PubMed/NCBI
|
|
9
|
Shirota Y, Ichikawa W, Uetake H, Yamada H,
Nihei Z and Sugihara K: Intratumoral dihydropyrimidine
dehydrogenase messenger RNA level reflects tumor progression in
human colorectal cancer. Ann Sur Oncol. 9:599–603. 2002. View Article : Google Scholar
|
|
10
|
Suda Y, Kuwashima Y, Tanaka Y, Uchida K,
Sakamoto H, Hashiguchi Y and Sekine T: Expression of thymidylate
synthase and thymidine phosphorylase in recurrence and survival
rates of advanced gastric cancer. Gastric Cancer. 2:165–172. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tanaka K, Otake K, Mohri Y, et al:
Clinical significance of the gene expression profile in residual
tumor cells after neoadjuvant chemoradiotherapy for esophageal
cancer. Oncol Rep. 21:1489–1494. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brücher BLDM, Keller G, Werner M, et al:
Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as
predictors for response, survival, and recurrence in patients with
esophageal squamous cell carcinoma following radiochemotherapy. Int
J Colorectal Dis. 24:69–77. 2009.PubMed/NCBI
|
|
13
|
Beck A, Etienne MC, Cheradame S, Fischel
JL, Formento P, Renee N and Milano G: A role for dihydropyrimidine
dehydrogenase and thymidylate synthase in tumour sensitivity to
fluorouracil. Eur J Cancer. 30A:1517–1522. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Danenberg KD, Salonga D, Park JM, et al:
Dihydropyrimidine dehydrogenase and thymidylate synthase gene
expression identify a high percentage of colorectal tumors
responding to 5-fluorouracil. Proc Am Soc Clin Oncol. 17:258–262.
1998.
|
|
15
|
Ichikawa W, Takahasi T, Suto K, et al:
Thymidylate synthase and dihydropyrimidine dehydrogenase gene
expression in relation to differentiation of gastric cancer. Int J
Cancer. 112:967–973. 2004. View Article : Google Scholar : PubMed/NCBI
|
